Vaccine for Oncology is under clinical development by MabVax Therapeutics Holdings and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Vaccine for Oncology’s likelihood of approval (LoA) and phase transition for Peritoneal Cancer took place on 17 Nov 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Vaccine for Oncology Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Vaccine for Oncology overview

Vaccine with QS-21 adjuvant is under development for the treatment of epithelial ovarian, fallopian tube and peritoneal cancers. It is administered through subcutaneous route. The Vaccine candidate comprises of GM2 ganglioside conjugated with immunostimulant keyhole limpet hemocyanin.

MabVax Therapeutics Holdings overview

MabVax Therapeutics Holdings (MabVax Therapeutics) formerly known as Telik is a clinical-stage biotechnology company that focuses on development of pipeline of human monoclonal antibody products for diagnosis and treatment of cancer.

Quick View Vaccine for Oncology LOA Data

Report Segments
  • Innovator
Drug Name
  • Vaccine for Oncology
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: MabVax Therapeutics Holdings
  • Originator: Memorial Sloan Kettering Cancer Center
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.